ZB011

ZB011 is an improved IGF-1R-targeted monoclonal antibody in development by Zenas BioPharma in collaboration with Viridian Therapeutics. It acts as an antagonist of the insulin-like growth factor 1 receptor (**IGF-1R**), blocking IGF-1R signaling to inhibit cell proliferation and survival, particularly in IGF-1R-expressing cells relevant to autoimmune and oncology contexts. Initially developed by Shanghai Zenas Biotechnology Co., Ltd., ZB011 aims to enhance dosing convenience and efficacy over predecessor antibodies like ZB001 (previously AVE-1642), with a global highest R&D status of preclinical, primarily targeted for Graves' ophthalmopathy (thyroid eye disease).